{"id":1652,"date":"2021-06-23T03:07:29","date_gmt":"2021-06-22T18:07:29","guid":{"rendered":"https:\/\/clarivate.com\/jp\/blog\/asco-2021-%e3%82%aa%e3%83%b3%e3%82%b3%e3%83%ad%e3%82%b8%e3%83%bc%e3%81%ae%e3%83%96%e3%83%ac%e3%82%a4%e3%82%af%e3%82%b9%e3%83%ab%e3%83%bc%e3%83%88%e3%83%83%e3%83%9710\/?lang=ja"},"modified":"2021-06-23T03:07:29","modified_gmt":"2021-06-22T18:07:29","slug":"top-10-oncology-breakthroughs-shared-at-asco-2021-2","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/blog\/top-10-oncology-breakthroughs-shared-at-asco-2021-2\/","title":{"rendered":"ASCO 2021: \u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u30d6\u30ec\u30a4\u30af\u30b9\u30eb\u30fc\u30c8\u30c3\u30d710"},"content":{"rendered":"<p><a href=\"https:\/\/clarivate.com\/blog\/top-10-oncology-breakthroughs-shared-at-asco-2021\/\">\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8<\/a><\/p>\n<p><span style=\"font-size: small\">\u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><em>\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u30012,400\u4ef6\u4ee5\u4e0a\u306b\u306e\u307c\u308bASCO\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u5206\u6790\u3057\u3001\u85ac\u7269\u6cbb\u7642\u306e\u5c55\u671b\u306b\u4e88\u60f3\u3055\u308c\u308b\u5f71\u97ff\u306b\u57fa\u3065\u3044\u3066\u30c8\u30c3\u30d710\u3092\u9078\u629e\u3057\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u30d6\u30ec\u30a4\u30af\u30b9\u30eb\u30fc\u306e\u5206\u6790\u7d50\u679c\u3001\u30c7\u30fc\u30bf\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306e\u7d4c\u55b6\u8005\u5411\u3051\u306e\u30d2\u30f3\u30c8\u3092\u3054\u7d39\u4ecb\u3057\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<h4><strong>&#8220;\u516c\u5e73\u306b: \u3059\u3079\u3066\u306e\u60a3\u8005\u306b\u3001\u3044\u3064\u3067\u3082\u3001\u3069\u3053\u3067\u3067\u3082&#8221;<\/strong><\/h4>\n<p>&nbsp;<\/p>\n<p>ASCO\u5e74\u6b21\u7dcf\u4f1a\u306f\u30011\u5e74\u306e\u3046\u3061\u3067\u6700\u5927\u306e\u816b\u760d\u5b66\u306e\u30a4\u30d9\u30f3\u30c8\u3067\u3059\u3002\u6628\u5e74\u306b\u5f15\u304d\u7d9a\u304d\u3001COVID-19\u306e\u4e16\u754c\u7684\u6d41\u884c\u306b\u3088\u308a\u30016\u67084\u65e5\u304b\u30898\u65e5\u307e\u3067\u30d0\u30fc\u30c1\u30e3\u30eb\u3067\u958b\u50ac\u3055\u308c\u307e\u3057\u305f\u3002\u4eca\u5e74\u306f\u3001\u300e\u516c\u5e73\u306b: \u3059\u3079\u3066\u306e\u60a3\u8005\u306b\u3001\u3044\u3064\u3067\u3082\u3001\u3069\u3053\u3067\u3067\u3082\uff08\u201cEquity: Every Patient. Everyday. Everywhere\u201d\uff09\u300f\u3068\u3044\u3046\u30c6\u30fc\u30de\u306e\u3082\u3068\u3001\u4eca\u5f8c\u306e\u7814\u7a76\u306e\u7126\u70b9\u3068\u306a\u308b\u5206\u91ce\u3092\u512a\u5148\u3057\u3001\u533b\u7642\u3092\u53d7\u3051\u3089\u308c\u306a\u3044\u60a3\u8005\u3055\u3093\u3092\u81e8\u5e8a\u7814\u7a76\u306b\u53c2\u52a0\u3055\u305b\u308b\u3053\u3068\u306e\u91cd\u8981\u6027\u3092\u5f37\u8abf\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001\u85ac\u7269\u6cbb\u7642\u306e\u4eca\u5f8c\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3068\u4e88\u60f3\u3055\u308c\u308b\u6cbb\u7642\u6cd5\u3092\u30ec\u30d3\u30e5\u30fc\u3059\u308b<a href=\"https:\/\/clarivate.com\/drugs-to-watch\/\">Drugs to Watch<\/a>\u30b7\u30ea\u30fc\u30ba\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u767a\u8868\u3055\u308c\u305f2,400\u4ef6\u4ee5\u4e0a\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u78ba\u8a8d\u3057\u3001\u305d\u306e\u4e2d\u304b\u3089\u30c8\u30c3\u30d710\u3092\u9078\u3073\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u306e\u5206\u6790\u7d50\u679c\u3068\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306e\u7d4c\u55b6\u8005\u306b\u3068\u3063\u3066\u306e\u30ad\u30fc\u30dd\u30a4\u30f3\u30c8\u3092\u7d39\u4ecb\u3057\u307e\u3059\u3002<\/p>\n<p>ASCO2021\u3067\u306f\u3001\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5e02\u5834\u306e\u30b9\u30da\u30af\u30c8\u30eb\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u591a\u304f\u306e\u30cb\u30e5\u30fc\u30b9\u304c\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u4eca\u5e74\u306e\u5e74\u6b21\u7dcf\u4f1a\u3067\u8a8d\u3081\u3089\u308c\u305f\u6700\u3082\u9855\u8457\u306a\u50be\u5411\u306e1\u3064\u306f\u3001\u6cbb\u7642\u56f0\u96e3\u306a\u304c\u3093\u3092\u542b\u3080\u65e9\u671f\u306e\u30d5\u30a7\u30fc\u30ba\uff08\u307e\u305f\u306f\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u8a2d\u5b9a\uff09\u306b\u304a\u3051\u308b\u6a19\u7684\u6cbb\u7642\u306e\u30c7\u30fc\u30bf\u3092\u5831\u544a\u3059\u308b\u6284\u9332\u306e\u6570\u3067\u3042\u308a\u3001\u5834\u5408\u306b\u3088\u3063\u3066\u306f\u85ac\u5264\u306b\u3088\u308b\u6cbb\u7642\u306e\u9078\u629e\u80a2\u304c\u306a\u3044\u3001\u307e\u305f\u306f\u5c11\u306a\u3044\u3053\u3068\u3082\u3042\u308a\u307e\u3059\u3002<\/p>\n<p>\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u305f\u4e3b\u8981\u306a\u30c7\u30fc\u30bf\u306e\u3088\u308a\u8a73\u7d30\u306a\u5206\u6790\u306b\u3064\u3044\u3066\u306f\u3001\u5f53\u793e\u306e\u5c02\u9580\u5bb6\u30c1\u30fc\u30e0\u304c\u63d0\u4f9b\u3059\u308b\u60c5\u5831\u306b\u3054\u6ce8\u76ee\u304f\u3060\u3055\u3044\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>1. \u5207\u9664\u53ef\u80fd\u306a\u65e9\u671fNSCLC\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u304c\u671f\u5f85\u3055\u308c\u308b<\/strong><\/h4>\n<p><em>\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u306f\u3001\u5207\u9664\u53ef\u80fd\u306a\u65e9\u671fNSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308bDFS\uff08\u7121\u75c5\u751f\u5b58\u671f\u9593\uff09\u306e\u6709\u610f\u306a\u6539\u5584\u306b\u3088\u308a\u3001\u7279\u5b9a\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3066\u627f\u8a8d\u3055\u308c\u305f\u6700\u521d\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u8907\u6570\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u304c\u3001\u5207\u9664\u53ef\u80fd\u306aNSCLC\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u8a55\u4fa1\u3055\u308c\u3066\u3044\u307e\u3059\u30022021\u5e743\u6708\u306b\u306f\u3001\u5b8c\u5168\u5207\u9664\u5f8c\u306b\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u5316\u5b66\u7642\u6cd5\u3092\u53d7\u3051\u305fIB-IIIA\u671f\u306eNSCLC\u3092\u5bfe\u8c61\u306b\u3001\u30ed\u30b7\u30e5\u793e\u306e\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u3068\u30d9\u30b9\u30c8\u30b5\u30dd\u30fc\u30c6\u30a3\u30d6\u30b1\u30a2\uff08BSC\uff09\u3092\u6bd4\u8f03\u8a55\u4fa1\u3057\u305f\u91cd\u8981\u306a\u7b2cIII\u76f8\u8a66\u9a13IMpower010\u304c\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bDFS\u3092\u9054\u6210\u3057\u3001\u3053\u306e\u6cbb\u7642\u6cd5\u3067\u6709\u610f\u306a\u81e8\u5e8a\u52b9\u679c\u3092\u793a\u3057\u305f\u521d\u3081\u3066\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3068\u306a\u308a\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong><a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.8500\" target=\"_blank\" rel=\"noopener\">\u305d\u306e\u7d50\u679c<\/a>\u3001\u816b\u760d\u7d30\u80de\u306e PD-L1 \u767a\u73fe\u7387\u304c 1%\u4ee5\u4e0a\u306e\u30b9\u30c6\u30fc\u30b8 II-IIIA \u60a3\u8005\uff08HR 0.66\u3001P = 0.0039\uff09\u3001\u304a\u3088\u3073\u7121\u4f5c\u70ba\u5316\u3055\u308c\u305f\u30b9\u30c6\u30fc\u30b8 II-IIIA NSCLC \u60a3\u8005\u5168\u54e1\uff08HR 0.79\u3001P = 0.0205\uff09\u306b\u304a\u3044\u3066\u3001\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u306f BSC \u306b\u5bfe\u3057\u3066 DFS \u3092\u6709\u610f\u306b\u6539\u5584\u3057\u307e\u3057\u305f\u3002\u672c\u89e3\u6790\u306e\u6642\u70b9\u3067\u306f\u3001\u5168\u6cbb\u7642\u76ee\u7684\u96c6\u56e3\uff08\u30b9\u30c6\u30fc\u30b8 IB-IIIA\uff09\u306b\u304a\u3044\u3066\u3001DFS \u306f\u6709\u610f\u5dee\u306e\u5883\u754c\u7dda\u3092\u8d8a\u3048\u3066\u304a\u3089\u305a\u3001\u5168\u751f\u5b58\u7387\u306e\u30c7\u30fc\u30bf\u306f\u672a\u6210\u719f\u3067\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>2. \u30ea\u30f3\u30d1\u30fc\u30b6\u306f\u3001\u751f\u6b96\u7d30\u80de\u7cfb<em>BRCA1\/2<\/em>\u907a\u4f1d\u5b50\u5909\u7570\u304a\u3088\u3073\u9ad8\u30ea\u30b9\u30af\u306eHER2\u9670\u6027\u65e9\u671f\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30d7\u30e9\u30bb\u30dc\u306b\u5bfe\u3057\u512a\u4f4d\u6027\u3092\u793a\u3059<\/strong><\/h4>\n<p><em>OlympiA\u306e\u30c7\u30fc\u30bf\u306b\u3088\u308a\u3001\u30ea\u30f3\u30d1\u30fc\u30b6\u306f\u65e9\u671f\u4e73\u304c\u3093\u5e02\u5834\u306e\u65e2\u5b58\u30d7\u30ec\u30a4\u30e4\u30fc\u3068\u306e\u7af6\u4e89\u3092\u6253\u7834\u3067\u304d\u308b\u306e\u304b\uff1f<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e742\u6708\u3001\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306f\u3001\u7b2c3\u76f8OlympiA\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u30ea\u30f3\u30d1\u30fc\u30b6\u304c<em>BRCA<\/em>\u5909\u7570\u3001\u30cf\u30a4\u30ea\u30b9\u30afHER2\u9670\u6027\u306e\u65e9\u671f\u4e73\u304c\u3093\u60a3\u8005\u306b\u304a\u3044\u3066\u3001\u30d7\u30e9\u30bb\u30dc\u3092\u4e0a\u56de\u308b\u512a\u308c\u305f\u4fb5\u8972\u6027DFS\u3068\u3044\u3046\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306f\u3001\u3053\u306e\u91cd\u8981\u306a\u8a66\u9a13\u306e\u3055\u3089\u306a\u308b\u30c7\u30fc\u30bf\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002OlympiA\u8a66\u9a13\u306f\u3001\u4ed6\u306ePARP\u963b\u5bb3\u5264\u304c\u8a55\u4fa1\u3055\u308c\u3066\u3044\u306a\u3044\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u306e\u8a2d\u5b9a\u3067\u30ea\u30f3\u30d1\u30fc\u30b6\u3092\u8abf\u67fb\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u8a2d\u5b9a\u3067\u30ea\u30f3\u30d1\u30fc\u30b6\u304c\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u3092\u5f97\u3089\u308c\u308c\u3070\u3001\u5b9a\u8a55\u306e\u3042\u308b\u6297PD-1\/PD-L1\u963b\u5bb3\u5264\u3067\u3042\u308b\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u3084\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u306e\u53b3\u3057\u3044\u7af6\u4e89\u306b\u76f4\u9762\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002PD-1\/PD-L1\u963b\u5bb3\u5264\u304c\u6df1\u304f\u9577\u3044\u81e8\u5e8a\u53cd\u5fdc\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308b\u3053\u3068\u3092\u8003\u3048\u308b\u3068\u3001\u533b\u5e2b\u306fPARP\u963b\u5bb3\u5264\u3088\u308a\u3082\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3092\u51e6\u65b9\u3059\u308b\u50be\u5411\u306b\u3042\u308b\u304b\u3082\u3057\u308c\u307e\u305b\u3093\u3002\u3055\u3089\u306b\u3001OlympiA\u8a66\u9a13\u306f\u3001<em>BRCA1\/2<\/em>\u907a\u4f1d\u5b50\u5909\u7570\u306e\u3042\u308b\u30c8\u30ea\u30d7\u30eb\u30cd\u30ac\u30c6\u30a3\u30d6\u4e73\u304c\u3093\u60a3\u8005\u3068\u3044\u3046\u5c0f\u3055\u306a\u60a3\u8005\u5c64\u3082\u30bf\u30fc\u30b2\u30c3\u30c8\u306b\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u3053\u308c\u3089\u306e\u6f5c\u5728\u7684\u306a\u969c\u5bb3\u306b\u3082\u304b\u304b\u308f\u3089\u305a\u3001\u533b\u5e2b\u305f\u3061\u306f\u30ea\u30f3\u30d1\u30fc\u30b6\u304cHER2\u9670\u6027\u306e<em>BRCA1\/2<\/em>\u5909\u7570\u306e\u9032\u884c\u4e73\u304c\u3093\u60a3\u8005\u306b\u6709\u52b9\u3067\u3042\u308b\u3053\u3068\u304c\u8a3c\u660e\u3055\u308c\u3066\u3044\u308b\u305f\u3081\u3001\u3053\u306e\u8a66\u9a13\u306e\u7d50\u679c\u3092\u5f85\u3061\u671b\u3093\u3067\u3044\u307e\u3059\u3002\u4eca\u56de\u306eOlympiA\u8a66\u9a13\u306e\u7d50\u679c\u304c\u6210\u529f\u3059\u308c\u3070\u3001\u65e9\u671f\u4e73\u304c\u3093\u306b\u304a\u3051\u308b\u30ea\u30f3\u30d1\u30fc\u30b6\u306e\u9069\u5fdc\u62e1\u5927\u3092\u652f\u6301\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u3001\u4e73\u304c\u3093\u306b\u304a\u3051\u308b\u30ea\u30f3\u30d1\u30fc\u30b6\u306e\u9069\u5fdc\u60a3\u8005\u6570\u3092\u5927\u5e45\u306b\u62e1\u5927\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>3. \u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u304c\u814e\u7d30\u80de\u304c\u3093\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u6709\u52b9\u6027\u3092\u793a\u3059<\/strong><\/h4>\n<p><em>\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306f\u3001\u814e\u7d30\u80de\u304c\u3093\u5e02\u5834\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u8a2d\u5b9a\u306b\u304a\u3051\u308b\u6297PD-1\/PD-L1\u7642\u6cd5\u306e\u9580\u6238\u3092\u958b\u304f\u3053\u3068\u306b\u306a\u308b\u306e\u304b\uff1f<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e744\u6708\u3001\u30e1\u30eb\u30af\u306fKEYNOTE-564\u8a66\u9a13\u3067\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b\u30d7\u30e9\u30bb\u30dc\u306b\u5bfe\u3059\u308bDFS\u3092\u9054\u6210\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u3001RCC\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u8a2d\u5b9a\u306b\u304a\u3051\u308b\u6297PD-1\/PD-L1\u7642\u6cd5\u306e\u6700\u521d\u306e\u80af\u5b9a\u7684\u306a\u7d50\u679c\u3092\u793a\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30e1\u30eb\u30af\u306f\u3001KEYNOTE-564\u8a66\u9a13\u306e\u4e88\u5099\u89e3\u6790\u7d50\u679c\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002KEYNOTE-564\u8a66\u9a13\u306f\u3001\u814e\u7d30\u80de\u304c\u3093\u60a3\u8005\u306e\u814e\u6458\u51fa\u8853\u5f8c\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3092\u8a55\u4fa1\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u814e\u7d30\u80de\u304c\u3093\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u306f\u672a\u958b\u62d3\u306e\u5e02\u5834\u3067\u3042\u308a\u3001\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306e\u6210\u9577\u306e\u53ef\u80fd\u6027\u3092\u79d8\u3081\u3066\u3044\u307e\u3059\u3002\u4eca\u56de\u306e\u30c7\u30fc\u30bf\u306f\u3001\u814e\u7d30\u80de\u304c\u3093\u306b\u304a\u3051\u308b\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u53ef\u80fd\u6027\u3092\u5e83\u3052\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u73fe\u5728\u627f\u8a8d\u3055\u308c\u3066\u3044\u308b\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u306e\u9032\u884c\u6027\u814e\u7d30\u80de\u304c\u3093\u306b\u5bfe\u3059\u308b\u30a2\u30ad\u30b7\u30c1\u30cb\u30d6\u3068\u306e\u4f75\u7528\u7642\u6cd5\u306e\u9069\u5fdc\u3092\u3055\u3089\u306b\u62e1\u5927\u3059\u308b\u3082\u306e\u3067\u3059\u3002<\/p>\n<p>\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u3078\u306e\u62e1\u5927\u306f\u3001\u3053\u306e\u75be\u60a3\u306e\u6cbb\u7642\u6cd5\u3092\u518d\u69cb\u7bc9\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u3001\u3053\u306e\u9069\u5fdc\u75c7\u306b\u304a\u3051\u308b\u30e9\u30a4\u30d5\u30b5\u30a4\u30af\u30eb\u30fb\u30de\u30cd\u30b8\u30e1\u30f3\u30c8\u306b\u5927\u304d\u306a\u30c1\u30e3\u30f3\u30b9\u3092\u3082\u305f\u3089\u3059\u3053\u3068\u306f\u9593\u9055\u3044\u3042\u308a\u307e\u305b\u3093\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>4. \u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u5207\u9664\u3055\u308c\u305f\u98df\u9053\u764c\u307e\u305f\u306f\u80c3\u98df\u9053\u63a5\u5408\u90e8\u764c\u306e\u8853\u5f8c\u88dc\u52a9\u7642\u6cd5\u3068\u3057\u3066\u9855\u8457\u306a\u6709\u52b9\u6027\u3092\u793a\u3059<\/strong><\/h4>\n<p><em>CheckMate-577\u8a66\u9a13\u306e\u30c7\u30fc\u30bf\u3092\u6b66\u5668\u306b\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u65e9\u671f\u306e\u98df\u9053\u30fb\u80c3\u98df\u9053\u63a5\u5408\u90e8\uff08GEJ\uff09\u304c\u3093\u306e\u6cbb\u7642\u7fd2\u6163\u3092\u5909\u3048\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e745\u6708\u3001\u7b2c3\u76f8\u306eCheckMate-577\u8a66\u9a13\u306eDFS\u306e\u7d50\u679c\u306b\u57fa\u3065\u304d\u3001FDA\u306f\u30cd\u30aa\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u3092\u53d7\u3051\u305f\u75c5\u7406\u5b66\u7684\u75c5\u5909\u304c\u6b8b\u5b58\u3059\u308b\u5b8c\u5168\u5207\u9664\u306e\u98df\u9053\u307e\u305f\u306fGEJ\u304c\u3093\u60a3\u8005\u306e\u6cbb\u7642\u306e\u305f\u3081\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u30aa\u30d7\u30b8\u30fc\u30dc\u3092\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u672c\u8a66\u9a13\u306e<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.4003\" target=\"_blank\" rel=\"noopener\">\u8ffd\u52a0\u30c7\u30fc\u30bf<\/a>\u3067\u306f\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u3092\u6295\u4e0e\u3057\u305f\u7fa4\u3068\u30d7\u30e9\u30bb\u30dc\u3092\u6295\u4e0e\u3057\u305f\u7fa4\u306e\u9593\u3067\u3001\u9060\u9694\u8ee2\u79fb\u306e\u306a\u3044\u751f\u5b58\u671f\u9593\u306e\u4e2d\u592e\u5024\u306b\u5927\u304d\u306a\u5dee\u304c\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\uff08\u305d\u308c\u305e\u308c28.3\u30ab\u6708\u5bfe17.6\u30ab\u6708\u3001HR 0.74\uff09\u3002\u307e\u305f\u3001\u60a3\u8005\u306eQOL\uff08\u751f\u6d3b\u306e\u8cea\uff09\u304c\u7dad\u6301\u3055\u308c\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u306e\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u304c\u81e8\u5e8a\u73fe\u5834\u3067\u7ba1\u7406\u53ef\u80fd\u3067\u3042\u308b\u3053\u3068\u3092\u793a\u3059\u30c7\u30fc\u30bf\u3082\u5f97\u3089\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u3001\u73fe\u5728\u3001\u4ed6\u306e\u6a19\u7684\u85ac\u5264\u304c\u627f\u8a8d\u3055\u308c\u3066\u3044\u306a\u3044\u98df\u9053\u304c\u3093\u3084GEJ\u304c\u3093\u306e\u8853\u5f8c\u88dc\u52a9\u7642\u6cd5\u306b\u304a\u3044\u3066\u3001\u65b0\u305f\u306a\u6a19\u6e96\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u78ba\u7acb\u3059\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002\u306a\u304a\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u3001\u7279\u5b9a\u306e\u60aa\u6027\u9ed2\u8272\u816b\u306e\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8853\u5f8c\u88dc\u52a9\u7642\u6cd5\u3068\u3057\u3066\u3082\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>5. \u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306f\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u4f75\u7528\u7642\u6cd5\u3092\u9032\u884c\u30fb\u8ee2\u79fb\u6027\u98df\u9053\u6241\u5e73\u4e0a\u76ae\u304c\u3093\u306e\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u85ac\u3068\u4f4d\u7f6e\u3065\u3051\u308b\u65b9\u91dd<\/strong><\/h4>\n<p><em>CheckMate-648\u306e\u30c7\u30fc\u30bf\u306b\u3088\u308a\u3001\u524d\u6cbb\u7642\u6b74\u306e\u306a\u3044\u60a3\u8005\u306b\u5bfe\u3059\u308b\u30aa\u30d7\u30b8\u30fc\u30dc\u4f75\u7528\u7642\u6cd5\u306e\u627f\u8a8d\u304c\u53ef\u80fd\u3068\u306a\u308b\u304c\u3001\u3053\u306e\u30bb\u30b0\u30e1\u30f3\u30c8\u3067\u306f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u306e\u7af6\u5408\u306b\u76f4\u9762\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u4ed6\u306e\u591a\u304f\u306e\u304c\u3093\u306e\u9069\u5fdc\u75c7\u3068\u540c\u69d8\u306b\u3001\u98df\u9053\u304c\u3093\u306b\u5bfe\u3057\u3066\u3082\u4f75\u7528\u7642\u6cd5\u306e\u958b\u767a\u304c\u884c\u308f\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306f\u3001\u5207\u9664\u4e0d\u80fd\u306a\u9032\u884c\u6027\u30fb\u8ee2\u79fb\u6027\u98df\u9053\u6241\u5e73\u4e0a\u76ae\u304c\u3093\uff08ESCC\uff09\u306b\u5bfe\u3059\u308b\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3068\u3057\u3066\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\uff0b\u30e4\u30fc\u30dc\u30a4\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\uff0b\u5316\u5b66\u7642\u6cd5\u3092\u8a55\u4fa1\u3057\u305f\u7b2c3\u76f8CheckMate-648\u8a66\u9a13\u306e\u7d50\u679c\u3092\u516c\u958b\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u672c\u8a66\u9a13\u304c\u6210\u529f\u3059\u308c\u3070\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u3068\u30e4\u30fc\u30dc\u30a4\u304a\u3088\u3073\uff0f\u307e\u305f\u306f\u30aa\u30d7\u30b8\u30fc\u30dc\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u7642\u6cd5\u304cFDA\u306b\u627f\u8a8d\u3055\u308c\u308b\u53ef\u80fd\u6027\u304c\u9ad8\u304f\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u8ee2\u79fb\u6027ESCC\u306e\u6cbb\u7642\u30d1\u30b9\u30a6\u30a7\u30a4\u306e\u4e2d\u3067\u3001\u3088\u308a\u65e9\u3044\u6bb5\u968e\u3067\u4f7f\u7528\u3055\u308c\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\uff08\u73fe\u5728\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u30d5\u30eb\u30aa\u30ed\u30d4\u30ea\u30b8\u30f3\u304a\u3088\u3073\u30d7\u30e9\u30c1\u30ca\u30d9\u30fc\u30b9\u306e\u5316\u5b66\u7642\u6cd5\u306e\u524d\u6cbb\u7642\u5f8c\u306b\u4f7f\u7528\u3059\u308b\u3053\u3068\u304c\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\uff09\u3002\u3057\u304b\u3057\u3001\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u7642\u6cd5\u306f\u3001\u3059\u3067\u306b\u5c40\u6240\u9032\u884c\u6027\u307e\u305f\u306f\u8ee2\u79fb\u6027\u306e\u98df\u9053\u30fb\u80c3\u8178\u304c\u3093\uff08CheckMate-648\u3067\u691c\u8a0e\u3055\u308c\u305f\u9069\u5fdc\u3088\u308a\u3082\u5e83\u3044\uff09\u306b\u5bfe\u3057\u3066\u627f\u8a8d\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u3092\u7528\u3044\u305f\u4f75\u7528\u7642\u6cd5\u306f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u306e\u6fc0\u3057\u3044\u7af6\u4e89\u306b\u3055\u3089\u3055\u308c\u308b\u3053\u3068\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>6. \u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3068\u30cf\u30fc\u30bb\u30d7\u30c1\u30f3\u304a\u3088\u3073\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u306b\u3088\u308a\u3001\u524d\u6cbb\u7642\u6b74\u306e\u306a\u3044HER2+\u8ee2\u79fb\u6027\u80c3\u304c\u3093\u307e\u305f\u306fGEJ\u817a\u304c\u3093\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306a\u6cbb\u7642\u30aa\u30d7\u30b7\u30e7\u30f3\u304c\u3082\u305f\u3089\u3055\u308c\u308b<\/strong><\/h4>\n<p><em>\u30c8\u30ea\u30d7\u30ec\u30c3\u30c8\u4f75\u7528\u7642\u6cd5\u306f\u3001\u5168\u594f\u529f\u7387\uff08ORR\uff09\u3068\u594f\u529f\u306e\u6301\u7d9a\u6027\u306b\u57fa\u3065\u3044\u3066\u3001\u7b2c\u4e00\u9078\u629e\u306e\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u80a2\u3092\u5e83\u3052\u307e\u3059<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e745\u6708\u3001\u7b2c3\u76f8KEYNOTE-811\u306e\u4e2d\u9593\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u304d\u3001FDA\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u306a\u3044\u8ee2\u79fb\u6027HER2+\u80c3\u304c\u3093\u307e\u305f\u306fGEJ\u304c\u3093\u306b\u5bfe\u3059\u308b\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\uff0b\u30cf\u30fc\u30bb\u30d7\u30c1\u30f3\u3068\u5316\u5b66\u7642\u6cd5\u306e\u4f75\u7528\u7642\u6cd5\u3092\u8fc5\u901f\u627f\u8a8d\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u3053\u306e\u8a66\u9a13\u306f\u3001\u30cf\u30fc\u30bb\u30d7\u30c1\u30f3\u3068\u5316\u5b66\u7642\u6cd5\u3092\u4f75\u7528\u3057\u305f\u30ad\u30a4\u30c8\u30eb\u30fc\u30c0\u3092\u3001\u8ee2\u79fb\u6027HER2\u967d\u6027\u80c3\u304c\u3093\u307e\u305f\u306fGEJ\u304c\u3093\u306e\u7b2c\u4e00\u9078\u629e\u85ac\u3068\u3057\u3066\u8a55\u4fa1\u3059\u308b\u3082\u306e\u3067\u3059\u3002<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.4013\" target=\"_blank\" rel=\"noopener\">\u672c\u8a66\u9a13\u306e\u7d50\u679c<\/a>\u306f\u3001\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308b\u30cf\u30fc\u30bb\u30d7\u30c1\u30f3\uff0b\u5316\u5b66\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u3066\u3001ORR\u304c\u6709\u610f\u306b\u6539\u5584\u3057\uff08\u305d\u308c\u305e\u308c74\uff05\u5bfe52\uff05\u3001P = 0.00006\uff09\u3001\u594f\u52b9\u671f\u9593\u306e\u4e2d\u592e\u5024\u3082\u540c\u7b49\uff0810.6\u30ab\u6708\u5bfe9.5\u30ab\u6708\uff09\u3067\u3042\u308a\u3001\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u6cbb\u7642\u3068\u540c\u69d8\u306e\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u304c\u78ba\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002FDA\u306b\u3088\u308b\u672c\u4f75\u7528\u7642\u6cd5\u306e\u65e9\u671f\u627f\u8a8d\u306f\u3001\u816b\u760d\u53cd\u5fdc\u3068\u53cd\u5fdc\u306e\u6301\u7d9a\u6027\u306b\u57fa\u3065\u3044\u3066\u884c\u308f\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u672c\u85ac\u306f\u3001HER2\u967d\u6027\u306e\u8ee2\u79fb\u6027\u80c3\u304c\u3093\u3084GEJ\u304c\u3093\u306e\u60a3\u8005\u3055\u3093\u306e\u9650\u3089\u308c\u305f\u9078\u629e\u80a2\u3068\u4e88\u5f8c\u306e\u60aa\u3055\u3092\u8003\u616e\u3059\u308b\u3068\u3001\u3053\u306e\u9069\u5fdc\u75c7\u306e\u60a3\u8005\u3055\u3093\u306b\u5927\u304d\u306a\u5229\u76ca\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u3057\u304b\u3057\u306a\u304c\u3089\u3001\u4e00\u90e8\u306e\u816b\u760d\u5185\u79d1\u533b\u306f\u3001\u672c\u5264\u3092\u81e8\u5e8a\u306b\u5e83\u304f\u63a1\u7528\u3059\u308b\u524d\u306b\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bPFS\u304a\u3088\u3073OS\u306e\u7d50\u679c\u3092\u5f85\u3064\u3053\u3068\u306b\u306a\u308b\u3067\u3057\u3087\u3046\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>7. LAG-3\uff08\u30ea\u30e9\u30c8\u30ea\u30de\u30d6\uff09\u3068PD-1\uff08\u30aa\u30d7\u30b8\u30fc\u30dc\uff09\u306e\u4f75\u7528\u7642\u6cd5\u306e\u521d\u306e\u7b2cIII\u76f8\u30c7\u30fc\u30bf\u3001\u304a\u3088\u3073\u60aa\u6027\u9ed2\u8272\u816b\u306e\u65b0\u305f\u306a\u6cbb\u7642\u30aa\u30d7\u30b7\u30e7\u30f3\u306b\u3064\u3044\u3066<\/strong><\/h4>\n<p><em>\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306e\u30ea\u30e9\u30c8\u30ea\u30de\u30d6\/\u30aa\u30d7\u30b8\u30fc\u30dc\u306f\u3001\u60aa\u6027\u9ed2\u8272\u816b\u306b\u5bfe\u3059\u308bPD-1\/CTLA-4\u4f75\u7528\u7642\u6cd5\uff08\u30aa\u30d7\u30b8\u30fc\u30dc\/\u30e4\u30fc\u30dc\u30a4\uff09\u306e\u30b7\u30a7\u30a2\u306b\u98df\u3044\u8fbc\u3080\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e743\u6708\u3001\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306f\u3001RELATIVITY-047\u304c\u30aa\u30d7\u30b8\u30fc\u30dc\u5358\u5264\u3068\u6bd4\u8f03\u3057\u3066\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bPFS\u3092\u9054\u6210\u3057\u305f\u3068\u767a\u8868\u3057\u3001\u304c\u3093\u9818\u57df\u306b\u304a\u3051\u308bLAG-3\u3068PD-1\u306e\u4f75\u7528\u7642\u6cd5\u306e\u521d\u306e\u30dd\u30b8\u30c6\u30a3\u30d6\u306a\u7b2cIII\u76f8\u8a66\u9a13\u3068\u306a\u308a\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u306a\u3044\u5207\u9664\u30fb\u8ee2\u79fb\u6027\u60aa\u6027\u9ed2\u8272\u816b\u3092\u5bfe\u8c61\u306b\u3001\u30ea\u30e9\u30c8\u30ea\u30de\u30d6\uff08LAG-3\uff09\u3068\u30aa\u30d7\u30b8\u30fc\u30dc\uff08PD-1\uff09\u306e\u4f75\u7528\u7642\u6cd5\u3092\u30aa\u30d7\u30b8\u30fc\u30dc\u5358\u72ec\u7642\u6cd5\u3068\u6bd4\u8f03\u3057\u305f\u7b2cII\/III\u76f8RELATIVITY-047\u8a66\u9a13\u306e\u7d50\u679c\u3092\u521d\u3081\u3066\u767a\u8868\u3057\u307e\u3057\u305f\uff08\u8a73\u7d30\u306f\u3001<a href=\"https:\/\/meetinglibrary.asco.org\/record\/201596\/abstract\" target=\"_blank\" rel=\"noopener\">\u3053\u3061\u3089<\/a>\u3068<a href=\"https:\/\/meetinglibrary.asco.org\/record\/195979\/abstract\" target=\"_blank\" rel=\"noopener\">\u3053\u3061\u3089<\/a>\u306e\u6284\u9332\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\uff09\u3002\u305d\u306e\u7d50\u679c\u3001\u4f75\u7528\u7642\u6cd5\u3067\u306f\u3001\u30aa\u30d7\u30b8\u30fc\u30dc\u5358\u72ec\u7642\u6cd5\u306b\u6bd4\u3079\u3066\u3001PFS\u306e\u4e2d\u592e\u5024\u304c5\u30ab\u6708\u6539\u5584\u3057\u307e\u3057\u305f\uff08\u305d\u308c\u305e\u308c\u300110.1\u30ab\u6708\u5bfe4.6\u30ab\u6708\uff09\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u30d6\u30ea\u30b9\u30c8\u30eb\u30fb\u30de\u30a4\u30e4\u30fc\u30ba \u30b9\u30af\u30a4\u30d6\u306e\u65b0\u898f\u56fa\u5b9a\u7528\u91cfLAG-3\/PD-1\u4f75\u7528\u7642\u6cd5\u306f\u3001\u30b4\u30fc\u30eb\u30c9\u30b9\u30bf\u30f3\u30c0\u30fc\u30c9\u3068\u306a\u308b\u5168\u751f\u5b58\u671f\u9593\uff08OS\uff09\u306e\u30c7\u30fc\u30bf\u306f\u307e\u3060\u5831\u544a\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u304c\u3001\u65e2\u306b\u78ba\u7acb\u3055\u308c\u3066\u3044\u308bCTLA-4\/PD-1\u4f75\u7528\u7642\u6cd5\u3068\u540c\u69d8\u306e\u6709\u52b9\u6027\u3092\u793a\u3057\u3066\u3044\u308b\u3068\u601d\u308f\u308c\u307e\u3059\uff08\u771f\u306e\u610f\u5473\u3067\u6bd4\u8f03\u3067\u304d\u308bhead-to-head\u306e\u30c7\u30fc\u30bf\u306f\u3042\u308a\u307e\u305b\u3093\u304c&#8230;\uff09\u3002\u307e\u305f\u3001LAG-3\/PD-1\u4f75\u7528\u7642\u6cd5\u306f\u3001\u3088\u308a\u5b89\u5168\u3067\u5fcd\u5bb9\u6027\u306e\u9ad8\u3044\u6cbb\u7642\u6cd5\u3068\u3044\u3048\u307e\u3059\u3002\u526f\u4f5c\u7528\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u304c\u512a\u308c\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001CTLA-4\/PD-1\u304b\u3089\u306e\u79fb\u884c\u304c\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>8. \u5370\u8c61\u7684\u306aORR\u30c7\u30fc\u30bf\u3092\u6b66\u5668\u306b\u3001ciltacabtagene autoleucel\u306f\u524d\u6cbb\u7642\u6b74\u306e\u591a\u3044\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308a\u5f97\u308b\u304b\uff1f<\/strong><\/h4>\n<p><em>ciltacabtagene autoleucel\u306f\u3001\u524d\u6cbb\u7642\u6b74\u306e\u591a\u3044\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u60a3\u8005\u306b\u5bfe\u3059\u308bBCMA\u3092\u6a19\u7684\u3068\u3057\u305f\u6cbb\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u30cf\u30fc\u30c9\u30eb\u3092\u9ad8\u304f\u3057\u3066\u3044\u307e\u3059<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u6700\u8fd1\u627f\u8a8d\u3055\u308c\u305fB\u7d30\u80de\u6210\u719f\u6297\u539f\uff08BCMA\uff09\u6a19\u7684\u85ac\u3067\u3042\u308b\u30a2\u30d9\u30af\u30de\uff08\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u3067FDA\u627f\u8a8d\u3092\u78ba\u4fdd\u3057\u305f\u6700\u521d\u306eCAR-T\u7d30\u80de\u7642\u6cd5\uff09\u3068\u30d6\u30ec\u30f3\u30ec\u30c3\u30d7\uff08\u6297\u4f53\u85ac\u7269\u8907\u5408\u4f53\uff09\u306f\u3001\u5c11\u306a\u304f\u3068\u30824\u3064\u306e\u524d\u6cbb\u7642\u30e9\u30a4\u30f3\u3092\u53d7\u3051\u305f\u60a3\u8005\u306e\u6cbb\u7642\u306b\u5bfe\u5fdc\u3057\u3066\u3044\u307e\u3059\u3002\u30e4\u30f3\u30bb\u30f3\u306f\u3001BCMA\u3092\u6a19\u7684\u3068\u3057\u305fCAR-T\u7d30\u80de\u7642\u6cd5\u3067\u3042\u308bciltacabtagene autoleucel\u306b\u3064\u3044\u3066\u30012020\u5e7412\u6708\u306bFDA\u306b\u751f\u7269\u5b66\u7684\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092\u30012021\u5e744\u6708\u306bEMA\u306b\u8ca9\u58f2\u627f\u8a8d\u7533\u8acb\uff08MAA\uff09\u3092\u305d\u308c\u305e\u308c\u63d0\u51fa\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u306f\u3001CARTITUDE-1\u3068\u3044\u3046\u7b2cIb\/II\u76f8\u81e8\u5e8a\u8a66\u9a13\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30de\u30eb\u30c1\u30b3\u30db\u30fc\u30c8\u3067\u5b9f\u65bd\u3055\u308c\u305f\u7b2cII\u76f8CARTITUDE-2\u8a66\u9a13\u306b\u304a\u3051\u308bciltacabtagene autoleucel\u306e<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.8013\" target=\"_blank\" rel=\"noopener\">\u30c7\u30fc\u30bf<\/a>\u3082\u540c\u69d8\u306b\u7d20\u6674\u3089\u3057\u3044\u3082\u306e\u3067\u3057\u305f\u3002\u672c\u5264\u306f\u30011\uff5e3\u7a2e\u985e\u306e\u524d\u6cbb\u7642\u3092\u53d7\u3051\u305f\u518d\u767a\uff0f\u96e3\u6cbb\u6027\u60a3\u8005\u306b\u304a\u3044\u3066\u300175\uff05\u306e\u53b3\u5bc6\u5b8c\u5168\u5bdb\u89e3\uff08sCR\uff09\u307e\u305f\u306f\u5b8c\u5168\u5bdb\u89e3\uff08CR\uff09\u3092\u542b\u308095\uff05\u306eORR\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u89b3\u5bdf\u671f\u9593\u306e\u4e2d\u592e\u5024\u306f5.8\u30ab\u6708\uff08\u30c7\u30fc\u30bf\u30ab\u30c3\u30c8\u30aa\u30d5\u6642\uff09\u3068\u77ed\u3044\u3067\u3059\u304c\u3001\u3053\u306e\u7b2c2\u76f8\u8a66\u9a13\u3067\u89b3\u5bdf\u3055\u308c\u305f\u65e9\u671f\u306e\u6df1\u3044\u53cd\u5fdc\u306f\u975e\u5e38\u306b\u6709\u671b\u3067\u3042\u308a\u3001ciltacabtagene autoleucel\u304c\u5e02\u5834\u306b\u51fa\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>ASCO\u3067\u306f\u3001BCMA\u3068CD3\u3092\u6a19\u7684\u3068\u3057\u305f\u30d0\u30a4\u30b9\u30da\u30b7\u30d5\u30a3\u30c3\u30af\u6297\u4f53\u30c6\u30af\u30ea\u30b9\u30bf\u30de\u30d6\uff08\u30e4\u30f3\u30bb\u30f3\uff09\u306e\u6700\u65b0\u306e\u7b2c1\u76f8\u30c7\u30fc\u30bf\u3082\u767a\u8868\u3055\u308c\u3001\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u304a\u3051\u308bBCMA\u3092\u6a19\u7684\u3068\u3057\u305f\u6cbb\u7642\u6cd5\u306e\u72b6\u6cc1\u306f\u307e\u3059\u307e\u3059\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>9. \u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u5bfe\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\uff1fhead-to-head\u306e\u30c7\u30fc\u30bf\u304cBTK\u963b\u5bb3\u5264\u306e\u5c06\u6765\u306e\u7af6\u4e89\u3092\u4fc3\u9032\u3059\u308b<\/strong><\/h4>\n<p><em>\u6162\u6027\u30ea\u30f3\u30d1\u6027\u767d\u8840\u75c5\uff08CLL\uff09\u306b\u304a\u3044\u3066\u3001\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306e\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001\u6a19\u6e96\u6cbb\u7642\u85ac\u3067\u3042\u308b\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u3068\u5dee\u5225\u5316\u3059\u308b\u306e\u306b\u5341\u5206\u306a\u306e\u304b\uff1f<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>\u30e4\u30f3\u30bb\u30f3\/\u30a2\u30c3\u30f4\u30a3\u306e\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u3068\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306f\u3001\u91cd\u8981\u306a\u7b2cIII\u76f8ELEVATE-RR\u8a66\u9a13\u3067\u8a55\u4fa1\u3055\u308c\u3066\u3044\u308b\u7d4c\u53e3BTK\u963b\u5bb3\u5264\u3067\u3059\u3002\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306f\u3001CLL\u306b\u5bfe\u3059\u308b\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u3092\u5f97\u305f2\u756a\u76ee\u306eBTK\u963b\u5bb3\u5264\u3067\u3042\u308a\u3001\u73fe\u5728\u306e\u6a19\u6e96\u6cbb\u7642\u3067\u3042\u308bImbruvica\u304c\u652f\u914d\u3059\u308b\u7af6\u4e89\u5e02\u5834\u306b\u53c2\u5165\u3057\u307e\u3059\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u9ad8\u30ea\u30b9\u30af\u306e\u518d\u767a\u30fb\u96e3\u6cbb\u6027 CLL \u3092\u5bfe\u8c61\u306b\u3001\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u3068\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u3092\u6bd4\u8f03\u3057\u305f\u521d\u306ehead-to-head\u8a66\u9a13\u306e<a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.7500\" target=\"_blank\" rel=\"noopener\">\u30c7\u30fc\u30bf<\/a>\u304c\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002\u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab\u306e\u975e\u52a3\u6027\u8a66\u9a13\u3067\u306f\u3001\u540c\u7b49\u306e\u6709\u52b9\u6027\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u304c\u3001\u5b89\u5168\u6027\u3068\u5fcd\u5bb9\u6027\u306b\u306f\u91cd\u8981\u306a\u9055\u3044\u304c\u3042\u308a\u3001\u5f8c\u7d9a\u306e\u6cbb\u7642\u30e9\u30a4\u30f3\u3067\u306e\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306e\u4f7f\u7528\u3092\u4fc3\u9032\u3059\u308b\u3082\u306e\u3068\u601d\u308f\u308c\u307e\u3059\u3002ELEVATE-RR\u8a66\u9a13\u3067\u306f\u3001\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306f\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u306b\u5bfe\u3057\u3066\u975e\u52a3\u6027\u3092\u793a\u3057\u3001\u4e21\u7fa4\u306ePFS\u306e\u4e2d\u592e\u5024\u306f38.4\u30ab\u6708\u3067\u3057\u305f\uff08OS\u306e\u4e2d\u592e\u5024\u306f\u672a\u5230\u9054\uff09\u3002\u7279\u306b\u3001\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b\u5168\u30b0\u30ec\u30fc\u30c9\u306e\u5fc3\u623f\u7d30\u52d5\u306b\u304a\u3044\u3066\u3001\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u306f\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u3088\u308a\u7d71\u8a08\u7684\u306b\u512a\u308c\u3066\u304a\u308a\u3001\u51fa\u8840\u30a4\u30d9\u30f3\u30c8\u306e\u767a\u751f\u983b\u5ea6\u3082\u5c11\u306a\u304f\u3001\u6cbb\u7642\u4e2d\u6b62\u3082\u5c11\u306a\u304b\u3063\u305f\u3002\u305f\u3060\u3057\u3001BTK\u963b\u5bb3\u5264\u3067\u306f\u3001\u982d\u75db\u3084\u54b3\u304c\u591a\u304f\u898b\u3089\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong>\u4eca\u56de\u306e\u30c7\u30fc\u30bf\u306f\u3001\u30a2\u30ab\u30e9\u30d6\u30eb\u30c1\u30cb\u30d6\u304c\u4eca\u5f8c\u3001\u5e02\u5834\u306b\u6d78\u900f\u3057\u3001\u518d\u767a\u30fb\u96e3\u6cbb\u6027\u306e\u60a3\u8005\u306b\u4f7f\u7528\u3055\u308c\u308b\u3053\u3068\u3092\u793a\u5506\u3057\u3066\u3044\u307e\u3059\u3002\u533b\u5e2b\u304chead-to-head\u306e\u30c7\u30fc\u30bf\u3092\u671b\u3080\u4e00\u65b9\u3067\u3001\u30a4\u30d6\u30eb\u30c1\u30cb\u30d6\u306e\u78ba\u56fa\u305f\u308b\u5730\u4f4d\u3092\u596a\u3046\u3053\u3068\u306f\u4f9d\u7136\u3068\u3057\u3066\u56f0\u96e3\u3067\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>10. <sup>177<\/sup>Lu-PSMA-617\u306eVISION\u30c7\u30fc\u30bf\u306f\u3001\u91cd\u5ea6\u306e\u524d\u51e6\u7f6e\u3092\u53d7\u3051\u305fmCRPC\u60a3\u8005\u306e\u65b0\u305f\u306a\u6cbb\u7642\u30aa\u30d7\u30b7\u30e7\u30f3\u3068\u306a\u308b<\/strong><\/h4>\n<p><em>\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u3092\u7528\u3044\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u306f\u3001\u5341\u5206\u306a\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u306a\u3044\u60a3\u8005\u5c64\u3092\u5bfe\u8c61\u3068\u3057\u3066\u3044\u307e\u3059\u304c\u3001\u3053\u306e\u6cbb\u7642\u6cd5\u304c\u65e5\u5e38\u8a3a\u7642\u306b\u3069\u306e\u7a0b\u5ea6\u5e83\u304f\u63a1\u7528\u3055\u308c\u308b\u3067\u3057\u3087\u3046\u304b\uff1f<\/em><\/p>\n<p><strong>\u80cc\u666f\uff1a<\/strong>2021\u5e743\u6708\u3001\u30ce\u30d0\u30eb\u30c6\u30a3\u30b9\u306f\u3001<sup>177<\/sup>Lu-PSMA-617\u304c\u3001\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u306e\u9ad8\u3044\u524d\u6cbb\u7642\u6b74\u306e\u591a\u3044\u60a3\u8005\u96c6\u56e3\u306b\u304a\u3044\u3066\u3001\u6a19\u6e96\u6cbb\u7642\u3068\u6bd4\u8f03\u3057\u3066\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bOS\u3068X\u7dda\u64ae\u5f71\u306b\u3088\u308b\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff08rPFS\uff09\u306e\u4e21\u65b9\u3092\u6e80\u305f\u3057\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p><strong>ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a<\/strong>\u30ce\u30d0\u30eb\u30c6\u30a3\u30b9\u306f\u3001VISION\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001PSMA\u3092\u6a19\u7684\u3068\u3057\u305f\u653e\u5c04\u6027\u30ea\u30ac\u30f3\u30c9\u6cbb\u7642\u85ac<sup>177<\/sup>Lu-PSMA-617\u306e<a href=\"https:\/\/meetinglibrary.asco.org\/record\/196661\/abstract\" target=\"_blank\" rel=\"noopener\">\u30c7\u30fc\u30bf<\/a>\u3092\u521d\u3081\u3066\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u5bfe\u8c61\u3068\u306a\u3063\u305f\u306e\u306f\u3001\u5c11\u306a\u304f\u3068\u30821\u7a2e\u985e\u306e\u30bf\u30ad\u30b5\u30f3\u7cfb\u85ac\u5264\u3068\u7b2c2\u4e16\u4ee3\u306e\u30db\u30eb\u30e2\u30f3\u7642\u6cd5\u306b\u3088\u308b\u524d\u6cbb\u7642\u6b74\u306e\u3042\u308b\u3001PSMA\u967d\u6027\u306e\u9032\u884c\u6027\u8ee2\u79fb\u6027\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\uff08mCRPC\uff09\u60a3\u8005\u3067\u3059\u3002\u653e\u5c04\u6027\u30ea\u30ac\u30f3\u30c9\u3092\u7528\u3044\u305f\u6cbb\u7642\u306b\u3088\u308a\u3001\u6a19\u6e96\u6cbb\u7642\u3068\u6bd4\u8f03\u3057\u3066\u3001\u7d71\u8a08\u7684\u306b\u6709\u610f\u306aOS\u306e\u6539\u5584\uff08p&lt;0.001\uff09\u3001\u6b7b\u4ea1\u30ea\u30b9\u30af\u306e38\uff05\u4f4e\u6e1b\u304c\u9054\u6210\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><strong>\u4eca\u5f8c\u306e\u5c55\u671b\uff1a<\/strong><sup>177<\/sup>Lu-PSMA-617\u306f\u65b0\u898f\u306e\u4f5c\u7528\u6a5f\u5e8f\u3092\u6709\u3057\u3066\u304a\u308a\u3001PSMA\u3092\u6a19\u7684\u3068\u3057\u305f\u3053\u306e\u6cbb\u7642\u6cd5\u306f\u3001\u91cd\u5ea6\u306e\u524d\u6cbb\u7642\u3092\u53d7\u3051\u3066\u3044\u308b\u60a3\u8005\u5c64\u306b\u5bfe\u3059\u308b\u4ee3\u66ff\u7642\u6cd5\u306e\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u304c\u9ad8\u3044\u3053\u3068\u304b\u3089\u3001\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u91cd\u8981\u306a\u306e\u306f\u3001\u9032\u884c\u6027\u524d\u7acb\u817a\u304c\u3093\u3067\u306fPSMA\u306e\u767a\u73fe\u91cf\u304c\u591a\u3044\u3053\u3068\u304b\u3089\u3001<sup>177<\/sup>Lu-PSMA-617\u306f\u6f5c\u5728\u7684\u306b\u5927\u304d\u306a\u60a3\u8005\u5c64\u3092\u30bf\u30fc\u30b2\u30c3\u30c8\u306b\u3057\u3066\u3044\u308b\u3053\u3068\u3067\u3059\u3002\u3057\u304b\u3057\u3001\u653e\u5c04\u6027\u533b\u85ac\u54c1\u3092\u7528\u3044\u305f\u6cbb\u7642\u3084\u7d39\u4ecb\u306e\u7d4c\u8def\u306f\u975e\u5e38\u306b\u8907\u96d1\u3067\u3042\u308a\u3001\u3053\u308c\u307e\u3067\u3053\u306e\u3088\u3046\u306a\u6cbb\u7642\u6cd5\u306f\u73fe\u5b9f\u4e16\u754c\u3067\u306f\u9650\u3089\u308c\u305f\u7bc4\u56f2\u3067\u3057\u304b\u63a1\u7528\u3055\u308c\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>\u4eca\u5e74\u306e\u5e74\u6b21\u7dcf\u4f1a\u3067\u306f\u3001\u75be\u60a3\u306e\u65e9\u671f\u6bb5\u968e\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\u6a19\u7684\u7642\u6cd5\u306e\u9032\u5c55\u306a\u3069\u3001\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u30c8\u30ec\u30f3\u30c9\u304c\u767a\u8868\u3055\u308c\u307e\u3057\u305f\u3002\u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u305f\u91cd\u8981\u306a\u30c7\u30fc\u30bf\u306e\u3088\u308a\u8a73\u7d30\u306a\u5206\u6790\u306b\u3064\u3044\u3066\u306f\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u5c02\u9580\u5bb6\u30c1\u30fc\u30e0\u306b\u3088\u308b\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u8a18\u4e8b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><em>\u3053\u306e\u8a18\u4e8b\u306b\u5bc4\u7a3f\u3057\u305f\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001Arman Esfandiari\u3001Carolina do Pazo\u3001Fiona Wiegert\u3001Grace Mitchell\u3001Laura Vinuesa\u3001Liseth Parra\u3001Priyanka Mehra\u3001Snigdha Gupta\u3001Sorcha Cassidy\u3001Anamika Ghosh\u3001Kurram Nawaz\u3001Rachel Webster\u3067\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>\u6025\u901f\u306b\u5909\u5316\u3059\u308b\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u306e\u72b6\u6cc1\u3092\u628a\u63e1\u3057\u3001\u30c7\u30fc\u30bf\u306b\u57fa\u3065\u3044\u305f\u610f\u601d\u6c7a\u5b9a\u3092\u884c\u3046\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u5f53\u793e\u306e<a href=\"https:\/\/clarivate.com\/products\/biopharma\/portfolio-strategy-business-development\/\">\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u6226\u7565\u304a\u3088\u3073\u4e8b\u696d\u958b\u767a\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306b\u3064\u3044\u3066\u306f\u3053\u3061\u3089<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>References<\/strong><\/p>\n<ol>\n<li><em><span style=\"font-size: small\">IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021; Abstract 8500.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1\/2 mutations and high risk HER2-negative early breast cancer. ASCO 2021; Abstract LBA1.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. ASCO 2021; Abstract LBA5.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021; Abstract 4003.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. Seeking approval, approved in ADC. ASCO 2021; Abstract LBA4001.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G\/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE- 811 study. 1L accelerated. ASCO 2021; Abstract 4013.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma. ASCO 2021; Abstract 9502<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). ASCO 2021; Abstract 9503.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. ASCO 2021; Abstract 8013.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). ASCO 2021; Abstract 8007.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. ASCO 2021; Abstract 7500.<\/span><\/em><\/li>\n<li><em><span style=\"font-size: small\">Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). ASCO 2021; Abstract LBA4.<\/span><\/em><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8 \u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002 &nbsp; \u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u30012,400\u4ef6\u4ee5\u4e0a\u306b\u306e\u307c\u308bASCO\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u5206\u6790\u3057\u3001\u85ac\u7269\u6cbb\u7642\u306e\u5c55\u671b\u306b\u4e88\u60f3\u3055\u308c\u308b\u5f71\u97ff\u306b\u57fa\u3065\u3044\u3066\u30c8\u30c3\u30d710\u3092\u9078\u629e\u3057\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u30d6\u30ec\u30a4\u30af\u30b9\u30eb\u30fc\u306e\u5206\u6790\u7d50\u679c\u3001\u30c7\u30fc\u30bf\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306e\u7d4c\u55b6\u8005\u5411\u3051\u306e\u30d2\u30f3\u30c8\u3092\u3054\u7d39\u4ecb\u3057\u307e\u3059\u3002 &nbsp; &#8220;\u516c\u5e73\u306b: \u3059\u3079\u3066\u306e\u60a3\u8005\u306b\u3001\u3044\u3064\u3067\u3082\u3001\u3069\u3053\u3067\u3067\u3082&#8221; &nbsp; ASCO\u5e74\u6b21\u7dcf\u4f1a\u306f\u30011\u5e74\u306e\u3046\u3061\u3067\u6700\u5927\u306e\u816b\u760d\u5b66\u306e\u30a4\u30d9\u30f3\u30c8\u3067\u3059\u3002\u6628\u5e74\u306b\u5f15\u304d\u7d9a\u304d\u3001COVID-19\u306e\u4e16\u754c\u7684\u6d41\u884c\u306b\u3088\u308a\u30016\u67084\u65e5\u304b\u30898\u65e5\u307e\u3067\u30d0\u30fc\u30c1\u30e3\u30eb\u3067\u958b\u50ac\u3055\u308c\u307e\u3057\u305f\u3002\u4eca\u5e74\u306f\u3001\u300e\u516c\u5e73\u306b: \u3059\u3079\u3066\u306e\u60a3\u8005\u306b\u3001\u3044\u3064\u3067\u3082\u3001\u3069\u3053\u3067\u3067\u3082\uff08\u201cEquity: Every Patient. Everyday. Everywhere\u201d\uff09\u300f\u3068\u3044\u3046\u30c6\u30fc\u30de\u306e\u3082\u3068\u3001\u4eca\u5f8c\u306e\u7814\u7a76\u306e\u7126\u70b9\u3068\u306a\u308b\u5206\u91ce\u3092\u512a\u5148\u3057\u3001\u533b\u7642\u3092\u53d7\u3051\u3089\u308c\u306a\u3044\u60a3\u8005\u3055\u3093\u3092\u81e8\u5e8a\u7814\u7a76\u306b\u53c2\u52a0\u3055\u305b\u308b\u3053\u3068\u306e\u91cd\u8981\u6027\u3092\u5f37\u8abf\u3057\u307e\u3057\u305f\u3002 \u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5c02\u9580\u5bb6\u306f\u3001\u85ac\u7269\u6cbb\u7642\u306e\u4eca\u5f8c\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3068\u4e88\u60f3\u3055\u308c\u308b\u6cbb\u7642\u6cd5\u3092\u30ec\u30d3\u30e5\u30fc\u3059\u308bDrugs to Watch\u30b7\u30ea\u30fc\u30ba\u306e\u4e00\u74b0\u3068\u3057\u3066\u3001\u767a\u8868\u3055\u308c\u305f2,400\u4ef6\u4ee5\u4e0a\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u3092\u78ba\u8a8d\u3057\u3001\u305d\u306e\u4e2d\u304b\u3089\u30c8\u30c3\u30d710\u3092\u9078\u3073\u307e\u3057\u305f\u3002\u4ee5\u4e0b\u306e\u8a18\u4e8b\u3067\u306f\u3001\u3053\u308c\u3089\u306e\u30a2\u30d6\u30b9\u30c8\u30e9\u30af\u30c8\u306e\u5206\u6790\u7d50\u679c\u3068\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306e\u7d4c\u55b6\u8005\u306b\u3068\u3063\u3066\u306e\u30ad\u30fc\u30dd\u30a4\u30f3\u30c8\u3092\u7d39\u4ecb\u3057\u307e\u3059\u3002 ASCO2021\u3067\u306f\u3001\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u5e02\u5834\u306e\u30b9\u30da\u30af\u30c8\u30eb\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u591a\u304f\u306e\u30cb\u30e5\u30fc\u30b9\u304c\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u4eca\u5e74\u306e\u5e74\u6b21\u7dcf\u4f1a\u3067\u8a8d\u3081\u3089\u308c\u305f\u6700\u3082\u9855\u8457\u306a\u50be\u5411\u306e1\u3064\u306f\u3001\u6cbb\u7642\u56f0\u96e3\u306a\u304c\u3093\u3092\u542b\u3080\u65e9\u671f\u306e\u30d5\u30a7\u30fc\u30ba\uff08\u307e\u305f\u306f\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u8a2d\u5b9a\uff09\u306b\u304a\u3051\u308b\u6a19\u7684\u6cbb\u7642\u306e\u30c7\u30fc\u30bf\u3092\u5831\u544a\u3059\u308b\u6284\u9332\u306e\u6570\u3067\u3042\u308a\u3001\u5834\u5408\u306b\u3088\u3063\u3066\u306f\u85ac\u5264\u306b\u3088\u308b\u6cbb\u7642\u306e\u9078\u629e\u80a2\u304c\u306a\u3044\u3001\u307e\u305f\u306f\u5c11\u306a\u3044\u3053\u3068\u3082\u3042\u308a\u307e\u3059\u3002 \u5e74\u6b21\u7dcf\u4f1a\u3067\u767a\u8868\u3055\u308c\u305f\u4e3b\u8981\u306a\u30c7\u30fc\u30bf\u306e\u3088\u308a\u8a73\u7d30\u306a\u5206\u6790\u306b\u3064\u3044\u3066\u306f\u3001\u5f53\u793e\u306e\u5c02\u9580\u5bb6\u30c1\u30fc\u30e0\u304c\u63d0\u4f9b\u3059\u308b\u60c5\u5831\u306b\u3054\u6ce8\u76ee\u304f\u3060\u3055\u3044\u3002 &nbsp; 1. \u5207\u9664\u53ef\u80fd\u306a\u65e9\u671fNSCLC\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u304c\u671f\u5f85\u3055\u308c\u308b \u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u306f\u3001\u5207\u9664\u53ef\u80fd\u306a\u65e9\u671fNSCLC\u60a3\u8005\u306b\u5bfe\u3059\u308bDFS\uff08\u7121\u75c5\u751f\u5b58\u671f\u9593\uff09\u306e\u6709\u610f\u306a\u6539\u5584\u306b\u3088\u308a\u3001\u7279\u5b9a\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3066\u627f\u8a8d\u3055\u308c\u305f\u6700\u521d\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 \u80cc\u666f\uff1a\u8907\u6570\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u304c\u3001\u5207\u9664\u53ef\u80fd\u306aNSCLC\u306e\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u7642\u6cd5\u3068\u3057\u3066\u8a55\u4fa1\u3055\u308c\u3066\u3044\u307e\u3059\u30022021\u5e743\u6708\u306b\u306f\u3001\u5b8c\u5168\u5207\u9664\u5f8c\u306b\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u5316\u5b66\u7642\u6cd5\u3092\u53d7\u3051\u305fIB-IIIA\u671f\u306eNSCLC\u3092\u5bfe\u8c61\u306b\u3001\u30ed\u30b7\u30e5\u793e\u306e\u30c6\u30bb\u30f3\u30c8\u30ea\u30af\u3068\u30d9\u30b9\u30c8\u30b5\u30dd\u30fc\u30c6\u30a3\u30d6\u30b1\u30a2\uff08BSC\uff09\u3092\u6bd4\u8f03\u8a55\u4fa1\u3057\u305f\u91cd\u8981\u306a\u7b2cIII\u76f8\u8a66\u9a13IMpower010\u304c\u3001\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308bDFS\u3092\u9054\u6210\u3057\u3001\u3053\u306e\u6cbb\u7642\u6cd5\u3067\u6709\u610f\u306a\u81e8\u5e8a\u52b9\u679c\u3092\u793a\u3057\u305f\u521d\u3081\u3066\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u3068\u306a\u308a\u307e\u3057\u305f\u3002 ASCO\u3067\u306e\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\uff1a\u305d\u306e\u7d50\u679c\u3001\u816b\u760d\u7d30\u80de\u306e PD-L1 \u767a\u73fe\u7387\u304c 1%\u4ee5\u4e0a\u306e\u30b9\u30c6\u30fc\u30b8 II-IIIA \u60a3\u8005\uff08HR&#8230;<\/p>\n","protected":false},"author":161,"featured_media":1653,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1297,1300,1228],"tags":[],"class_list":["post-1652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-cortellis","category-life-sciences-healthcare","clarivate-industry-life-sciences-and-healthcare","clarivate-product-biopharma","clarivate-product-hospital-healthcare-provider","clarivate-product-medtech","clarivate-product-reports"],"acf":[],"lang":"ja","translations":{"ja":1652},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/161"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=1652"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/1652\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/1653"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=1652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=1652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=1652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}